Repare Therapeutics (RPTX) Price & Analysis

Compare

447 Followers

RPTX Stock Chart & Stats

$2.65

-$0.07(-5.15%)

At close: Jan 08 4:00 PM EST

$2.65

-$0.07(-5.15%)

Day’s Range― - ―

52-Week Range$0.89 - $2.66

Previous CloseN/A

Volume283.97K

Average Volume (3M)138.92K

Market Cap

$114.24M

Enterprise Value$41.75M

Total Cash (Recent Filing)$112.60M

Total Debt (Recent Filing)$342.00K

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Mar 03, 2026

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.08

Shares Outstanding43,108,360

10 Day Avg. Volume221,679

30 Day Avg. Volume138,921

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.37

Price to Sales (P/S)1.04

P/FCF Ratio-0.73

Enterprise Value/Market Cap0.37

Enterprise Value/Revenue3.52

Enterprise Value/Gross Profit4.08

Enterprise Value/Ebitda-0.58

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Acquisition PremiumDefinitive acquisition agreement includes a premium to the previous closing price, providing immediate upside for shareholders upon deal close.

Analyst SentimentAnalyst reiterates a Buy rating while lowering the price target, signaling sustained confidence in the company's strategic value despite updated projections.

Liquidity EventAgreement creates a defined liquidity event that removes public-market execution risk and offers shareholders a clear exit path.

Bears Say

Clinical Data ConcernsEarly clinical results showed a low response rate and notable safety issues, raising questions about the lead program's viability and future development prospects.

Deal Consideration UncertaintyPurchase consideration tied to the company's cash balance after transaction fees and outstanding liabilities creates uncertainty around the actual cash payout to shareholders.

Valuation PressureAnalyst removal of projected revenues for the troubled asset and expectations of limited value from any contingent payout point to meaningful downward pressure on the company's valuation.

Repare Therapeutics News

Repare Therapeutics shareholders approve acquisition by XenoTherapeutics

Repare Therapeutics (RPTX) announced that its shareholders have approved the acquisition of all of the issued and outstanding...

14d ago

RPTX

Repare Therapeutics completes acquisition and goes private

Repare Therapeutics ( ($RPTX) ) has provided an announcement. On January 28, 2026, Repare Therapeutics completed its acquisition...

2d ago

RPTX

Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics

Repare Therapeutics ( ($RPTX) ) has shared an announcement. On January 16, 2026, Repare Therapeutics’ shareholders overwhelmingly approved...

14d ago

RPTX

Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million

Repare Therapeutics ( ($RPTX) ) has issued an announcement. Repare Therapeutics has entered into an asset purchase agreement...

25d ago

RPTX

Repare Therapeutics Sells RP-3467 Program to Gilead

Repare Therapeutics ( ($RPTX) ) has issued an update. On December 23, 2025, Repare Therapeutics entered into an...

1M ago

RPTX

Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout

The latest announcement is out from Repare Therapeutics ( ($RPTX) ). Repare Therapeutics has signed an asset purchase...

1M ago

RPTX

Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M

Repare Therapeutics (RPTX) announced a definitive asset purchase agreement for Gilead Sciences (GILD) to acquire Repare’s polymerase theta...

1M ago

GILD

RPTX

Repare Therapeutics announces CSO resignation and transition plan

An announcement from Repare Therapeutics ( ($RPTX) ) is now available. On December 18, 2025, Repare Therapeutics announced...

1M ago

RPTX

Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval

New activity is brewing for Repare Therapeutics ( ($RPTX) ). The company has submitted a Form DEFM14A to...

2M ago

RPTX

Repare Therapeutics Reports Positive Q3 2025 Results

Repare Therapeutics Inc ( ($RPTX) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

RPTX

Repare Therapeutics Announces Acquisition by XenoTherapeutics

An update from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therapeutics Inc. has entered into an...

2M ago

RPTX

Repare Therapeutics downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Marc Frahm downgraded Repare Therapeutics (RPTX) to Hold from Buy after the company agreed to...

2M ago

RPTX

Repare Therapeutics to be Acquired by XenoTherapeutics in Strategic Move

Repare Therapeutics ( ($RPTX) ) has issued an update. Repare Therapeutics has announced a definitive agreement to be...

3M ago

RPTX

Repare Therapeutics trading resumes

17:10 EST Repare Therapeutics (RPTX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

3M ago

RPTX

RPTX FAQ

What was Repare Therapeutics Inc’s price range in the past 12 months?

Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $2.66 in the past 12 months.

What is Repare Therapeutics Inc’s market cap?

Repare Therapeutics Inc’s market cap is $114.24M.

When is Repare Therapeutics Inc’s upcoming earnings report date?

Repare Therapeutics Inc’s upcoming earnings report date is Mar 03, 2026 which is in 32 days.

How were Repare Therapeutics Inc’s earnings last quarter?

Repare Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.313.

Is Repare Therapeutics Inc overvalued?

According to Wall Street analysts Repare Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Repare Therapeutics Inc pay dividends?

Repare Therapeutics Inc does not currently pay dividends.

What is Repare Therapeutics Inc’s EPS estimate?

Repare Therapeutics Inc’s EPS estimate is -0.29.

How many shares outstanding does Repare Therapeutics Inc have?

Repare Therapeutics Inc has 43,108,360 shares outstanding.

What happened to Repare Therapeutics Inc’s price movement after its last earnings report?

Repare Therapeutics Inc reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went up 32.121%.

Which hedge fund is a major shareholder of Repare Therapeutics Inc?

Currently, no hedge funds are holding shares in RPTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Repare Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-49.78%

Trailing 12-Months

Asset Growth

-44.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Repare Therapeutics Inc

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Repare Therapeutics (RPTX) Earnings & Revenues

Historic Earnings Reports

RPTX Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.4,2.2,2,1.8,1.6,1.4,1.2,1,0.8,0.6000000000000001,0.3999999999999999,0.19999999999999973,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.4,2.2,2,1.8,1.6,1.4,1.2,1,0.8,0.6000000000000001,0.3999999999999999,0.19999999999999973,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.6,2.4,2.2,2,1.8,1.6,1.4,1.2,1,0.8,0.6000000000000001,0.3999999999999999,0.19999999999999973,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >